For a Topical Steroid, Bioequivalence Is Measured in Skin
FDA's 2026 guidance compares a proposed generic corticosteroid with its reference through a qualified skin-blanching method. The formulation and study conditions matter.
The skin response is the comparison
In July 2026, the US FDA finalized guidance for demonstrating in vivo bioequivalence of topical dermatologic corticosteroids submitted through the generic-drug pathway. It replaces the agency’s 1995 guidance. Its scope is specific: topical corticosteroids in abbreviated new drug applications, across potency groups. It is not a general test for every cream or skin-delivery platform. [1]
A corticosteroid can constrict blood vessels in the dermis, temporarily lightening the application site. Under controlled conditions, this skin-blanching response can serve as a surrogate for the rate and extent to which the drug becomes available at its site of action. The guidance recommends measuring that response with a qualified method, rather than assuming that matching active ingredients and strengths establish the same local behavior. [1]
First find a useful dose duration
The recommended in vivo approach has two studies. A pilot study applies the reference product for different durations and maps the dose-duration response. It identifies a range in which the assay can distinguish a change in exposure. A pivotal study then compares the proposed generic with the reference under the conditions established in the pilot. Instrument and operator qualification help keep measurement variation from obscuring that comparison. [1]
For a development team, the sequence matters. A poorly discriminating application time or inconsistent color measurement can make an otherwise carefully formulated product difficult to evaluate. The pivotal result is meaningful only in the context of the selected conditions and the response of eligible participants.
The finished product remains part of the evidence
FDA also notes that an in vitro characterization-based approach may be acceptable when formulation differences are not expected to significantly affect local or systemic availability. This is a conditional alternative, not a blanket exemption from evidence. Applicants are encouraged to discuss a proposed approach with FDA where scientific questions remain. [1]
The practical question is therefore not simply whether two labels name the same drug. It is whether the proposed finished product can support a defensible comparison at the relevant skin site, with a method sensitive enough to detect a difference. That lesson is relevant to formulation planning; the FDA guidance itself applies to the specified generic corticosteroid pathway.